Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Wyeth BMP-2 Should Be Limited To “Problem” Fractures – Panel

This article was originally published in The Gray Sheet

Executive Summary

Wyeth's InductOs recombinant human bone morphogenic protein-2 indications for use should be limited to "problem" fractures, according to FDA's Orthopaedic and Rehabilitation Devices Panel

You may also be interested in...



Medtronic InFuse bone graft

Long-awaited PMA approval granted for treating acute, open fractures of the tibial shaft with the product, which combines recombinant human bone morphogenetic protein (rhBMP-2) and an absorbable collagen sponge. Developed and manufactured by Wyeth and marketed by Medtronic Sofamor Danek, InFuse is inserted after a fracture has been stabilized with an intermedullary nail. Previously approved for use with a spinal fusion cage for degenerative disc disease (InFuse/LT-Cage) and intended to enhance bone healing, the product was recommended for broader approval by FDA's Orthopaedic & Rehabilitation Devices Panel in 2002 (1"The Gray Sheet" Nov. 25, 2002, p. 15). Since July 2003, the device has been marketed in Europe as InductOs...

Medtronic InFuse bone graft

Long-awaited PMA approval granted for treating acute, open fractures of the tibial shaft with the product, which combines recombinant human bone morphogenetic protein (rhBMP-2) and an absorbable collagen sponge. Developed and manufactured by Wyeth and marketed by Medtronic Sofamor Danek, InFuse is inserted after a fracture has been stabilized with an intermedullary nail. Previously approved for use with a spinal fusion cage for degenerative disc disease (InFuse/LT-Cage) and intended to enhance bone healing, the product was recommended for broader approval by FDA's Orthopaedic & Rehabilitation Devices Panel in 2002 (1"The Gray Sheet" Nov. 25, 2002, p. 15). Since July 2003, the device has been marketed in Europe as InductOs...

New CBER Panel Should Be Established For Combo Products Review – AAOS

A new FDA advisory panel under the purview of the Center for Biologics Evaluation & Research should be created specifically to review combination products, the American Academy of Orthopaedic Surgeons recommends

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT017543

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel